Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E S Ratner

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Doklady Akademii Nauk SSSR|August 11, 1972
[Elementary theory of threshold values of twilight vision]E S Ratner, Iu Z Matskovskaia
Doklady Akademii Nauk SSSR|November 11, 1973
[Relation of threshold contrast to object form]E S Ratner, Iu Z Matskovskaia
Analytical Biochemistry|September 13, 2015
A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic rangesP G Penketh, K Shyam, R P Baumann, et al.
Journal of Pediatric Orthopedics|March 1, 1987
Trabecular bone mineral density in idiopathic scoliosisS D Cook, A F Harding, E L Morgan, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Doklady Akademii Nauk SSSR|August 11, 1972
[Elementary theory of threshold values of twilight vision]E S Ratner, Iu Z Matskovskaia
Doklady Akademii Nauk SSSR|November 11, 1973
[Relation of threshold contrast to object form]E S Ratner, Iu Z Matskovskaia
Analytical Biochemistry|September 13, 2015
A simple and inexpensive method to control oxygen concentrations within physiological and neoplastic rangesP G Penketh, K Shyam, R P Baumann, et al.
Journal of Pediatric Orthopedics|March 1, 1987
Trabecular bone mineral density in idiopathic scoliosisS D Cook, A F Harding, E L Morgan, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Pageof 1